#India #Mumbai #Lupin Limited #Yabao Pharmaceuticals #Oseltamivir Phosphate

Lupin's Historic Approval for Oseltamivir Phosphate in China

In an important advancement for its global operations, Lupin Limited, a leading figure in the pharmaceutical industry, has received approval from the National Medical Products Administration of China for its Abbreviated New Drug Application regarding Oseltamivir Phosphate. This drug will be distributed in China in collaboration with Yabao Pharmaceuticals, a prominent player in the pediatric medicine sector. This event marks Lupin's inaugural entry into the Chinese market, an essential first step within one of the largest global pharmaceutical arenas.

A Step Towards Pediatric Treatment

The approved product, Oseltamivir Phosphate oral suspension (6 mg/mL), is specifically formulated for children, aiming to broaden accessibility for the pediatric population. It is approved for:

• - Treating influenza A and B in individuals starting from 2 weeks of age.
• - Preventing influenza A and B in those aged 1 year and older.

This initiative furthers Lupin’s commitment to delivering affordable and high-quality medicines for patients, particularly children who are often the most vulnerable to illnesses like influenza. The introduction of this drug is expected to greatly benefit patients and healthcare providers in China, where access to effective treatments is crucial.

Leaders Speak

Fabrice Egros, President of Corporate Development at Lupin, expressed excitement about this milestone. He stated, “We are delighted that we have received approval for Oseltamivir Oral Suspension in China. This is a strategic step in our entry into one of the world’s largest pharmaceutical markets.” This comment underlines Lupin's dedication to expanding its reach and presence in a market that holds immense potential for growth.

Wei Ren, President of Yabao Pharmaceuticals, reflected on the successful partnership, noting, “We are pleased to announce the official approval of Oseltamivir Oral Suspension in China, marking a key milestone in our partnership with Lupin.” Yabao’s commitment to quality pediatric medicine aligns with Lupin’s goals, creating a collaborative effort aimed at enhancing healthcare solutions for children’s health.

Lupin’s Global Reach

Headquartered in Mumbai, India, Lupin Limited operates in over 100 markets worldwide and is respected for its diverse portfolio comprising branded and generic drugs, biotechnology products, and more. The company’s global footprint is further supported by its advanced manufacturing and research capabilities, including 15 state-of-the-art manufacturing sites and 7 research centers across various regions.

Lupin is particularly well-positioned in India and the US, focusing on numerous therapeutic areas such as respiratory health, cardiovascular issues, and anti-infective treatments. With a workforce of over 24,000 professionals, Lupin continues to prioritize improved health outcomes through its subsidiaries which include Lupin Diagnostics and Lupin Digital Health.

Conclusion

The entry of Oseltamivir Phosphate into the Chinese market is not merely a business achievement for Lupin but a significant contribution to public health. As the company advances its mission of making high-quality medicines accessible to those who need them, this approval sets the stage for further innovations and partnerships in the future. The path forward looks promising as Lupin continues to explore opportunities and grow its global presence.